Hinge Health (NYSE:HNGE) CFO James Budge Sells 5,906 Shares

Hinge Health Inc. (NYSE:HNGE) CFO James Budge sold 5,906 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $54.82, for a total transaction of $323,766.92. Following the completion of the transaction, the chief financial officer owned 386,293 shares of the company’s stock, valued at $21,176,582.26. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Budge also recently made the following trade(s):

• On Monday, March 23rd, James Budge sold 11,006 shares of Hinge Health stock. The stock was sold at an average price of $42.26, for a total transaction of $465,113.56.

Hinge Health Trading Up 0.8%

Shares of NYSE HNGE opened at $55.17 on Wednesday. Hinge Health Inc. has a 12 month low of $30.08 and a 12 month high of $62.18. The firm has a market capitalization of $4.35 billion and a PE ratio of -4.47. The firm has a fifty day simple moving average of $43.58 and a two-hundred day simple moving average of $44.12.

Hinge Health (NYSE:HNGE) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.12 by $0.33. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business had revenue of $182.31 million during the quarter. During the same quarter last year, the company posted $1.30 earnings per share. The firm’s revenue for the quarter was up 47.2% compared to the same quarter last year. On average, sell-side analysts predict that Hinge Health Inc. will post 0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on HNGE. Stifel Nicolaus increased their price objective on shares of Hinge Health from $59.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Freedom Capital raised shares of Hinge Health to a “strong-buy” rating in a report on Thursday, January 22nd. Barclays raised their price target on shares of Hinge Health from $52.00 to $62.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Raymond James Financial reaffirmed an “outperform” rating and set a $70.00 price target on shares of Hinge Health in a report on Wednesday, May 6th. Finally, Needham & Company LLC raised their price target on shares of Hinge Health from $59.00 to $63.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $67.40.

Hedge Funds Weigh In On Hinge Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Hinge Health by 22.6% in the third quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company’s stock worth $60,753,000 after buying an additional 228,234 shares during the last quarter. Tudor Investment Corp ET AL boosted its holdings in shares of Hinge Health by 25.9% in the third quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company’s stock worth $18,467,000 after buying an additional 77,464 shares during the last quarter. First Eagle Investment Management LLC purchased a new position in shares of Hinge Health in the third quarter worth approximately $4,074,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Hinge Health by 755.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock worth $1,271,000 after buying an additional 24,155 shares during the last quarter. Finally, Braidwell LP purchased a new position in shares of Hinge Health in the third quarter worth approximately $44,686,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.